Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
1. A solid composition for oral administration comprising a GLP-1 agonist, a salt of N-(8-(2-hydroxybenzyol)amino)caprylic acid, and at least one excipient selected from the group consisting of a lubricant, binder, and filler;
wherein the GLP-1 agonist is semaglutide; and
wherein the composition comprises at least 60% (w/w) of the salt of N-(8-(2-hydroxybenzyol)amino)caprylic acid.
2. The composition according to claim 1 , wherein the composition is in the form of a tablet.
3. The composition according to claim 1 , wherein the salt of N-(8-(2-hydroxybenzyol)amino)caprylic acid is sodium N-(8-(2-hydroxybenzyol)amino)caprylate (SNAC).
4. The composition according to claim 1 , wherein the amount of the salt of N-(8-(2-hydroxybenzyol)amino)caprylic acid is in the range of 0.6-2.1 mmol.
5. The composition according to claim 1 , wherein the amount of the semaglutide is in the range of 0.01 mg to 100 mg.
6. The composition according to claim 1 , wherein the amount of the semaglutide is in the range of 0.01 to 25 μmol.
7. The composition according to claim 1 , wherein the lubricant is magnesium stearate.
8. The composition according to claim 1 , wherein the binder is povidone.
9. The composition according to claim 1 , wherein the filler is microcrystalline cellulose.